These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 26230853

  • 21. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
    Vandecaveye V, Michielsen K, De Keyzer F, Laleman W, Komuta M, Op de beeck K, Roskams T, Nevens F, Verslype C, Maleux G.
    Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
    [Abstract] [Full Text] [Related]

  • 22. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
    Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, Bhagat N, Cosgrove DP, Pawlik TM, Mezey E, Eng J, Kamel IR.
    Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632
    [Abstract] [Full Text] [Related]

  • 23. Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization.
    Kim BK, Kim SU, Kim MJ, Kim KA, Kim DY, Park JY, Ahn SH, Han KH, Chon CY.
    Clin Cancer Res; 2013 Mar 15; 19(6):1503-11. PubMed ID: 23225115
    [Abstract] [Full Text] [Related]

  • 24. Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma.
    Shim JH, Lee HC, Won HJ, Shin YM, Kim KM, Lim YS, Suh DJ.
    J Hepatol; 2012 Feb 15; 56(2):406-11. PubMed ID: 21782761
    [Abstract] [Full Text] [Related]

  • 25. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?
    Sahu S, Schernthaner R, Ardon R, Chapiro J, Zhao Y, Sohn JH, Fleckenstein F, Lin M, Geschwind JF, Duran R.
    Radiology; 2017 Jun 15; 283(3):883-894. PubMed ID: 27831830
    [Abstract] [Full Text] [Related]

  • 26. Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma.
    Vicentin I, Mosconi C, Garanzini E, Sposito C, Serenari M, Buscemi V, Verna M, Spreafico C, Golfieri R, Mazzaferro V, De Carlis L, Cescon M, Ercolani G, Vanzulli A, Cucchetti A.
    Eur Radiol; 2021 Dec 15; 31(12):8903-8912. PubMed ID: 34117911
    [Abstract] [Full Text] [Related]

  • 27. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment.
    Kim MN, Kim BK, Han KH, Kim SU.
    Expert Rev Gastroenterol Hepatol; 2015 Mar 15; 9(3):335-48. PubMed ID: 25370168
    [Abstract] [Full Text] [Related]

  • 28. Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses.
    Riaz A, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora R, Kulik L, Desai K, Thornburg B, Mouli S, Hickey R, Miller FH, Yaghmai V, Ganger D, Lewandowski RJ, Salem R.
    Hepatology; 2018 Mar 15; 67(3):873-883. PubMed ID: 28833344
    [Abstract] [Full Text] [Related]

  • 29. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
    Camacho JC, Kokabi N, Xing M, Prajapati HJ, El-Rayes B, Kim HS.
    J Vasc Interv Radiol; 2014 Feb 15; 25(2):256-65. PubMed ID: 24461131
    [Abstract] [Full Text] [Related]

  • 30. Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma.
    Choi J, Shim JH, Shin YM, Kim KM, Lim YS, Lee HC.
    J Hepatol; 2014 Jun 15; 60(6):1212-8. PubMed ID: 24486088
    [Abstract] [Full Text] [Related]

  • 31. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers.
    Chapiro J, Duran R, Lin M, Schernthaner RE, Wang Z, Gorodetski B, Geschwind JF.
    Radiology; 2015 May 15; 275(2):438-47. PubMed ID: 25531387
    [Abstract] [Full Text] [Related]

  • 32. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.
    Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Gupta R, Wang E, Baker T, Abecassis M, Benson AB, Nemcek AA, Omary R, Salem R.
    JAMA; 2010 Mar 17; 303(11):1062-9. PubMed ID: 20233824
    [Abstract] [Full Text] [Related]

  • 33. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.
    Vouche M, Kulik L, Atassi R, Memon K, Hickey R, Ganger D, Miller FH, Yaghmai V, Abecassis M, Baker T, Mulcahy M, Nayar R, Lewandowski RJ, Salem R.
    Hepatology; 2013 Nov 17; 58(5):1655-66. PubMed ID: 23703789
    [Abstract] [Full Text] [Related]

  • 34. Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma.
    Seyal AR, Gonzalez-Guindalini FD, Arslanoglu A, Harmath CB, Lewandowski RJ, Salem R, Yaghmai V.
    Hepatology; 2015 Oct 17; 62(4):1111-21. PubMed ID: 25999236
    [Abstract] [Full Text] [Related]

  • 35. Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization.
    Kim BK, Kim KA, Kim MJ, Park JY, Kim DY, Ahn SH, Han KH, Kim SU, Park MS.
    Dig Liver Dis; 2015 Aug 17; 47(8):682-8. PubMed ID: 25977216
    [Abstract] [Full Text] [Related]

  • 36. Assessment of treatment response in hepatocellular carcinoma: a review of the literature.
    Maida M, Cabibbo G, Brancatelli G, Genco C, Alessi N, Genova C, Romano P, Raineri M, Giarratano A, Midiri M, Cammà C.
    Future Oncol; 2013 Jun 17; 9(6):845-54. PubMed ID: 23718305
    [Abstract] [Full Text] [Related]

  • 37. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants.
    Bargellini I, Bozzi E, Campani D, Carrai P, De Simone P, Pollina L, Cioni R, Filipponi F, Bartolozzi C.
    Eur J Radiol; 2013 May 17; 82(5):e212-8. PubMed ID: 23332890
    [Abstract] [Full Text] [Related]

  • 38. The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation?
    Liu Q, Li A, Sun S, Luo R, Chen F.
    J BUON; 2014 May 17; 19(2):398-405. PubMed ID: 24965398
    [Abstract] [Full Text] [Related]

  • 39. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
    Ichikawa T, Machida N, Sasaki H, Tenmoku A, Kaneko H, Negishi R, Oi I, Fujino MA.
    Oncology; 2016 May 17; 91(6):317-330. PubMed ID: 27784014
    [Abstract] [Full Text] [Related]

  • 40. Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma.
    Ogasawara S, Kanai F, Ooka Y, Motoyama T, Suzuki E, Tawada A, Chiba T, Yokosuka O.
    Hepatol Int; 2013 Jun 17; 7(2):703-13. PubMed ID: 26201804
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.